NASDAQ:SIEN - Sientra Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $18.98 +0.44 (+2.37 %) (As of 11/15/2018 04:00 PM ET)Previous Close$18.54Today's Range$18.39 - $19.3852-Week Range$8.79 - $26.79Volume234,309 shsAverage Volume413,653 shsMarket Capitalization$503.63 millionP/E Ratio-6.73Dividend YieldN/ABeta-0.37 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. It also provides body contouring products; facial and nasal implants; saline-filled breast implant sizers to identify the correct style and size of implants; and non-breast tissue expanders for expanding tissue and skin surface area for burn care and other reconstructive use. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California. Receive SIEN News and Ratings via Email Sign-up to receive the latest news and ratings for SIEN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical appliances & supplies Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SIEN Previous Symbol CUSIPN/A Webwww.sientra.com Phone805-562-3500 Debt Debt-to-Equity Ratio0.36 Current Ratio2.77 Quick Ratio2.34 Price-To-Earnings Trailing P/E Ratio-6.73 Forward P/E Ratio-6.33 P/E GrowthN/A Sales & Book Value Annual Sales$36.54 million Price / Sales14.86 Cash FlowN/A Price / CashN/A Book Value$3.08 per share Price / Book6.16 Profitability EPS (Most Recent Fiscal Year)($2.82) Net Income$-64,020,000.00 Net Margins-126.03% Return on Equity-132.84% Return on Assets-54.84% Miscellaneous Employees200 Outstanding Shares28,600,000Market Cap$503.63 million OptionableOptionable Sientra (NASDAQ:SIEN) Frequently Asked Questions What is Sientra's stock symbol? Sientra trades on the NASDAQ under the ticker symbol "SIEN." How were Sientra's earnings last quarter? Sientra Inc (NASDAQ:SIEN) announced its quarterly earnings data on Tuesday, November, 6th. The medical instruments supplier reported ($0.72) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.67) by $0.05. The medical instruments supplier had revenue of $16.90 million for the quarter, compared to analysts' expectations of $16.66 million. Sientra had a negative return on equity of 132.84% and a negative net margin of 126.03%. Sientra's revenue was up 72.4% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.74) earnings per share. View Sientra's Earnings History. When is Sientra's next earnings date? Sientra is scheduled to release their next quarterly earnings announcement on Tuesday, March 12th 2019. View Earnings Estimates for Sientra. What price target have analysts set for SIEN? 9 brokerages have issued twelve-month target prices for Sientra's shares. Their predictions range from $16.00 to $31.00. On average, they expect Sientra's share price to reach $24.1429 in the next year. This suggests a possible upside of 27.2% from the stock's current price. View Analyst Price Targets for Sientra. What is the consensus analysts' recommendation for Sientra? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sientra in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sientra. What are Wall Street analysts saying about Sientra stock? Here are some recent quotes from research analysts about Sientra stock: 1. According to Zacks Investment Research, "Sientra, Inc. is a medical aesthetics company. The Company offers plastic surgery implantable devices for cosmetic and reconstructive surgery, including Breast Implants, Tissue Expanders, Body Contouring, Implants and Specialty Products. Sentra's primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. It also offers a range of other aesthetic and specialty products. Sientra, Inc. is headquartered in Santa Barbara, California. " (11/7/2018) 2. Canaccord Genuity analysts commented, "We reiterate our BUY rating on Sientra following strong Q1/18 results that came in slightly ahead of prelim results. SIEN has had a busy start to the year executing on key initiatives that leave us incrementally more confident in the company’s ability to deliver upside to estimates moving forward. Specifically, SIEN received FDA approval of the company’s new manufacturing facility and immediately re-entered the US breast implant market early in the Q2, posted a robust Q1 that showed continued momentum in tissue expander sales as well as encouraging signs of a turnaround in the miraDry business, and lastly completed a $108M (net of fees) capital raise." (5/10/2018) Has Sientra been receiving favorable news coverage? Media headlines about SIEN stock have been trending neutral on Thursday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Sientra earned a daily sentiment score of 0.2 on InfoTrie's scale. They also assigned news headlines about the medical instruments supplier a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the company's share price in the next several days. Who are some of Sientra's key competitors? Some companies that are related to Sientra include Establishment Labs (ESTA), RTI Surgical (RTIX), Invacare (IVC), Lakeland Industries (LAKE), ConforMIS (CFMS), Rewalk Robotics (RWLK), COLLPLANT HOLDI/S (CLGN), NanoVibronix (NAOV), Histogenics (HSGX), Precision Therapeutics (AIPT), Wound Management Technologies (WNDM), Allied Healthcare Products (AHPI), Avitar (AVTI), Bionik Laboratories (BNKL) and Halyard Health (HYH). Who are Sientra's key executives? Sientra's management team includes the folowing people: Mr. Jeffrey M. Nugent, Chairman & CEO (Age 71)Mr. Charles Huiner, COO and Sr. VP of Corp. Devel. & Strategy (Age 47)Mr. Patrick F. Williams, Sr. VP & GM of miraDry (Age 45)Mr. Keith J. Sullivan, Director & Advisor (Age 60)Mr. Paul Sean Little, CFO, Sr. VP & Treasurer (Age 53) Who are Sientra's major shareholders? Sientra's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.53%), Gilder Gagnon Howe & Co. LLC (4.59%), Columbus Circle Investors (1.51%), United Services Automobile Association (0.83%), Bank of New York Mellon Corp (0.78%) and EAM Investors LLC (0.76%). Company insiders that own Sientra stock include Jeffrey M Nugent, Patrick F Williams, R Scott Greer and Timothy Haines. View Institutional Ownership Trends for Sientra. Which major investors are selling Sientra stock? SIEN stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Bridgeway Capital Management Inc., Axiom International Investors LLC DE, Birchview Capital LP, EAM Investors LLC, Columbus Circle Investors and Wells Fargo & Company MN. Company insiders that have sold Sientra company stock in the last year include Jeffrey M Nugent and Timothy Haines. View Insider Buying and Selling for Sientra. Which major investors are buying Sientra stock? SIEN stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., BlackRock Inc., Russell Investments Group Ltd., Quantum Capital Management, AMS Capital Ltda, United Services Automobile Association, Suffolk Capital Management LLC and Blair William & Co. IL. Company insiders that have bought Sientra stock in the last two years include Jeffrey M Nugent, Patrick F Williams, R Scott Greer and Timothy Haines. View Insider Buying and Selling for Sientra. How do I buy shares of Sientra? Shares of SIEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Sientra's stock price today? One share of SIEN stock can currently be purchased for approximately $18.98. How big of a company is Sientra? Sientra has a market capitalization of $503.63 million and generates $36.54 million in revenue each year. The medical instruments supplier earns $-64,020,000.00 in net income (profit) each year or ($2.82) on an earnings per share basis. Sientra employs 200 workers across the globe. What is Sientra's official website? The official website for Sientra is http://www.sientra.com. How can I contact Sientra? Sientra's mailing address is 420 SOUTH FAIRVIEW AVENUE SUITE 200, SANTA BARBARA CA, 93117. The medical instruments supplier can be reached via phone at 805-562-3500 or via email at [email protected] MarketBeat Community Rating for Sientra (NASDAQ SIEN)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 170 (Vote Outperform)Underperform Votes: 200 (Vote Underperform)Total Votes: 370MarketBeat's community ratings are surveys of what our community members think about Sientra and other stocks. Vote "Outperform" if you believe SIEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SIEN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/15/2018 by MarketBeat.com StaffFeatured Article: What is a Market Correction?